Home
About UsHealth Plan Care Managers
- Health technology assessments
- Comparative effectiveness reviews
- Coverage policy support
- Clinical guideline development
- Program evaluation
|
A woman-owned health technology research and consulting firm dedicated to improving health outcomes through the use of evidence. We evaluate a wide variety of medical technologies to determine clinical effectiveness, comparative effectiveness, safety, and impact. |
|
Unbiased, evidence-based research and analysis of new, evolving, existing, and controversial healthcare technologies to support health plans in the development of defensible, transparent coverage policies, care management protocols, and clinical practice guidelines. |
|
Unbiased, evidence-based assessments to help hospitals evaluate the impact of new, evolving, existing, and controversial healthcare technologies on safety, patient outcomes, internal resources, and return on investment (ROI). |
|
Expertise in providing unbiased evidence synthesis and health technology assessments, coupled with an understanding of government healthcare programs, provides a trust-worthy resource for policy makers, government agencies and contractors. |
|
A workplace benefit that provides personalized and confidential evidence-based information to employees experiencing disruptive health events. |
 |
Listen Now: Hospital CMOs Can Lead the Charge to Drive Out CostsA case based approach to illustrate how using a standardized, evidence-based process to negotiate price allows organizations to maximize vendor contracts and drive down price while improving clinical value. |
 |
NEW White Paper: Taking Hospital Cost-Reduction Efforts to the Next LevelThere is no argument that traditional value-analysis approaches, such as contracting and standardization strategies, have eliminated much misuse and wasteful consumption, especially with regard to physician preference items (PPIs). The missing link in these efforts, however, has been scientific evidence of patient outcomes and safety. |
 |
Genetic testing must have more oversightKnowledge of genetics has the potential to rapidly revolutionize medical understanding of a disease state and improve treatment and patient outcomes. With any type of genetic or molecular testing, but especially with those marketed directly to consumers, there needs to be a level of regulatory oversight that ensures that the test does what it says it will do and predicts what it says it will predict. |
 |
Evidence must become the neutral groundIt’s time for things to change. I’m issuing a challenge in 2013 — let’s stop talking about the importance of evidence and start actually incorporating proof of clinical value into our utilization management and value analysis processes. |
 |
NEW White Paper: Gene Patenting in the United States – Where Have We Been, Where Are We Going?This white paper is designed to provide an overview of the history of gene patenting in the United States, summarize the Myriad patent challenge, review the approaches used in other countries, and identify future challenges. |
Social Media
|
© 1996-2012 Winifred S. Hayes, Inc. All Rights Reserved.